Blood Marker Shows Promise for Tracking Oxaliplatin-Related Nerve Damage
· newswise.com · popularity 19/100 · 0 similar stories today · Science & Research Methods (Discovery & Research)
Read the original at newswise.com →
Summary
<img src="https://www.newswise.com/legacy/image.php?image=https://media.newswise.com/pio/articles/858179/6af09cc5ce7d9_1_858179.jpg&width=100&height=150" alt="Newswise image" />A research team has found preliminary evidence that a blood-based marker of nerve injury could help researchers track peripheral neurotoxicity caused by oxaliplatin, a chemotherapy drug used to treat colorectal cancer. In a study of 28 patients, serum neurofilament light chain (sNfL) increased during treatment and remained elevated three months afterward, alongside worsening neuropathy assessments. Higher follow-up concentrations were associated with more severe clinical signs and patient-reported symptoms. The findings suggest that sNfL could complement existing assessments in trials evaluating interventions to prevent chemotherapy-related nerve damage, providing an objective measure of changes in nerve injury.
Found in: Newswise. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 7.